Oncology Pharma and Ribera Solutions Signed a Licensing Agreement for the Use of Ribera’s Clinical Trials Platform, Connect2Med
San Francisco, CA - ( NewMediaWire ) - November 06, 2019 - Oncology Pharma Inc. (OTCPK: ONPH) is pleased to announce that it has entered into an agreement with Ribera for its clinical trial platform, “Connect2Med”. The license by Ribera of its “Connect2Med” for human clinical trials to Oncology Pharma shall be exclusive for oncology, drug development, clinical trials, personalized oncology and therapeutics worldwide, including the right to sub-license, with one year to complete certain milestones, including modifications for oncology use and an option to purchase the platform or renew the license agreement.
Ribera Solutions is a software services firm focused on the development of technologies for the life sciences, medical devices, healthcare and clinical research sectors. The firm provides technology consulting, research and development on cloud, mobile and web-based connected care solutions. Ribera develops its own proprietary software applications that can be licensed for running clinical trials, providing “connected” care services, and for collection of remote data and analysis.
Dr. Mahant (CSO COO) stated: “The iOS and Android based mobile “Connect2Med” App is a powerful tool that is centralized, has recruitment features, the potential to improve participant retention, participant tracking, and the App will be in compliance with local and Federal regulations such as HIPAA.”
Dr. Stefan Gruenwald (Scientific Advisor and Board Member, Oncology Pharma, Inc.) believes that Ribera’s Connect2Med is one of the best digital platforms for patient engagement and retention. It is designed to advance clinical trials for pharmaceutical and diagnostic / medical device companies by improving patient retention rate and engagement through real-time communication. Through medical device connectivity patients can schedule and perform tele-health examinations with hospitals and clinics. Powerful artificial intelligence and Smart Health Applications deliver relevant content directly to the user, which can be customized for data analysis and reports in real-time.
ABOUT ONCOLOGY PHARMA, INC. (www.oncology-pharma.com)
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”) is a pioneering oncology company dedicated to developing, manufacturing, and commercializing therapeutics. The Company has licensed Tulynode’s patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. The Company is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
ABOUT Ribera Solutions, LLC (www.riberasolutions.com)
Ribera Solutions (CA, USA) has developed Web based Connect2Med platform with iOS and Android mobile Apps. Ribera’s mission is to provide solutions for solving challenging problems timely through simple, practical and economical approaches.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company’s financial position.
CONTACTS:For additional Information, please contact the Oncology Pharma at:One Sansome Street, Suite 3500San Francisco, CA 94104Phone: 415-869-1038 Fax: 415-946-8801 website: email: email@example.com